Article25: Right to an adequate standard of living

Everyone has the right to a standard of living adequate for the health and well-being of him/herself...

The Universal Declaration of Human Rights
United Nations. December 10, 1948


Investment strategy

A diversified portfolio with an optimized risk-reward approach

Meaningful investments in areas of unmet need in healhcare, coordinated to make a substantial social impact within a predefined time frame.


fund capital Flagship Growth

Industrial and healthcare infrastructure, risk-mitigated impactment investment projects


Advanced Radiotherapy Technologies

Integrated Proton/RT/Imaging centers and technologies


fund capital Breakthrough

Transformational investments in innovative projects in lifesciences, biotech and technology




News Highlights – May 2022

There were several highlights in May about new approvals for targeted treatments, deals for companion diagnostics and updates on drug development. May 26 was the due-date for in vitro medical devices to meet criteria of the new European IVD regulation. A day circled in red by diagnostic companies undergoing product certification, since low-risk IVDs have been postponed depending on class risk:...

Read more

News Highlights – April 2022

This spring opened with a number of compelling progresses in the adoption of diagnostics, especially in Europe.

Genetron Health obtained CE Mark for its Seq-MRD for patients with B lymphocytic leukemia and multiple myeloma before and after treatment. Lunit obtained CE mark for its Lunit Scope PD-L1 TPS, an AI-based test to analyze PD-L1 expression in both tumor and inflammatory cells from...

Read more

News Highlights – March 2022

This month confirms a focus of companies and institutions on precision medicine to advance patients' testing and treatments, with more and more opportunities made available throughout the entire globe.

The Spanish Societies of Oncology and Pathology issued an official claim to the NHS for the coverage of biomarker testing and to establish reference centers for NGS in the National territory....

Read more

News Highlights – February 2022

This February witnessed an update for the EU Parliament for the Fight Against Cancer Plan, several collaborations for CDx developments, as well as new Dx launches, especially for IVD tests for early-stage cancer.

AmoyDx partnered with Pierre Fabre to develop a CDx in China to detect BRAF mutation in tumor samples and select patients eligible for Braftovi (encorafenib) with or without Mektovi...

Read more

News Highlights – January 2022

This year’s opening was flagged by several announcements on clinical application of advanced tools for molecular diagnostics as well as new deals for precision oncology.

The JP Morgan Healthcare Conference showcased major healthcare companies and their strategic plans foreseen for 2022. Illumina introduced Chemistry X, a new breakthrough technology advancing current sequencing status, and...

Read more

Summary of the year 2021

There is no doubt that in 2021 precision oncology made huge steps forward on the promise of targeted treatment, both on biomarkers as well on new therapies, especially in lung and breast cancer, with CRC as an emerging indication.

Indeed, one of the most remarkable breakthrough of the year are KRAS G12C inhibitors for NSCLC, along with different strategies to select patients by both tissue or...

Read more

News Highlights – December 2021

The closing of 2021 brought outstanding news on the accessibility of predictive diagnostics in Europe with key government decisions taken by two Member States.

In Spain, National Healthcare will incorporate predictive genetic analysis with public funding in the healthcare portfolio of common specialized care services, while Italy will establish regional Molecular Tumor Boards (MTBs) allowing...

Read more

News Highlights – November 2021

In this late fall the development of advanced diagnostics tests is fueled by new companies' partnerships, regulatory approvals and public funding worldwide.

In the liquid biopsy space, Burning Rock and Merck KGaA entered a CDx agreement for the MET inhibitor tepotinib in the Chinese market with the OncoCompass Target. AstraZeneca started a strategic collaboration with Saga Diagnostics to...

Read more

News Highlights – October 2021

October was pivotal month for biomarker testing landscape, especially for EU countries due to the updates on the implementation of the upcoming IVDR, extending the transition phase to cancer diagnosis IVD products, delaying 1 to 3 years depending on the product.

ESMO updated clinical practice guidelines for metastatic breast cancer. Patients with TNBC tumor should get PD-L1 testing and...

Read more

News Highlights – September 2021

September is a month with important milestones presented during ESMO and WCLC. Outstanding results from DESTINY trials paved the way for new therapeutic options and clinical standards based on Daiichi-Sankio’s conjugated MoAb ENHERTHU (trastuzumab-deruxtecan) for patients with lung, gastric and breast cancer. Impressive clinical outcomes also by IMFINZI in NSCLC (plus I/O) and in SCLC....

Read more

News Highlights – July 2021

The month of July started with College of American Pathologists releasing an update to the CAP Cancer Protocols with updated report guidance for routinely tested biomarkers. Among the protocols with significant review are lung and head and neck biomarkers, as well as quantitative IHC reporting.

On the CDx field, Foundation Medicine got two new CDx approvals: ALK for NSCLC patients in...
Read more

News Highlights – June 2021

The beginning of this summer saw an important landmark with the WHO report on AI application in healthcare, which includes the six key principles for AI design and use: autonomy, beneficence, transparency, responsibility and accountability, equity and sustainability. The report release is aligned with recent proliferation of AI platforms for big data management and data generation as well as...
Read more

News Highlights – May 2021

May marks an important milestone for long unmet needs for cancer patients: Amgen’s sotorasib (Lumakras), the first KRAS G12C monoclonal for advanced NSCLC, and Janssen’s amivantamab-vmjw (Rybrevant) for the treatment of NSCLC with EGFR exon 20 insertion mutations received a fast track approval by FDA . While Qiagen's Therascreen KRAS RGQ PCR is the CDx for KRAS tissue analysis,...
Read more

News Highlights – April 2021

April followed the trend of March, with many advances in the liquid biopsy field. At the same time, there is an increasing interest in regulating the space, as the European Commission is moving forward with its appraisal of the impact of Grail’s acquisition by Illumina on the EU market.

On the diagnostic side, France has started changes in its testing funding system, with the inclusion of...
Read more

News Highlights – March 2021

March 2021 witnessed interesting developments in the landscape of precision oncology. Several companies joined forces to expand their portfolio of NGS solutions and optimize data management, including Bio-techne, Agilent and Merck, making a tender offer for the public stocks of Pandion Therapeutics.

Among this month's FDA drug approvals, Pfizer’s Lorbrena (Lornatinib) indication was...
Read more

Impact of testing centralisation on patients in the UK

From our series focusing on testing centralisation in the UK, we address here a major downstream effect, its impact on patients, and discuss how to overcome the current associated challenges.
Read more

Centralisation in the time of pandemic

This third article in our series, deciphering the diagnostic testing organisation in the UK, recapitulates lessons learned from local initiatives during the COVID-19 pandemic to adjust the current centralisation of tests.
Read more

The State of Centralisation of Pathology and Molecular Testing in England

This second article, from our series deciphering the evolution of the testing landscape in the UK, analyses the current centralisation of tests of both Pathology and Genomics, its origin and the challenges yet to be solved for a fully operational and compliant centralised system.
Read more

The future of molecular testing within the UK

This is the first of a series of articles on molecular testing centralisation in the UK outlining the landscape as well as its impact on patient treatment.
Read more

NGS Panels in Management of Myeloid-related Diseases

IPBA-led workshop during the 2019 European Hematology Association meeting, Amsterdam
Read more

Changing the game of precision medicine in the Land of the Rising Sun

Recent changes in the reimbursement system and the strategy of the Ministry of Health are contributing to the current upswing in momentum and pivot towards precision medicine in the clinic in Japan.
Read more

Inflection Point Biomedical Advisors (IPBA) provides effective strategic advice and implement hands-on, innovative projects in Precision Medicine for the pharmaceutical and diagnostics industry, investment and VC funds as well as to EU and US governmental agencies.

IPBA is a key collaborator and vital partner of Article25 Impact Ventures

About IPBA